Dysesthesia: A New Signal for Retatrutide The TRIUMPH-4 Phase 3 trial revealed an unexpected finding: dysesthesia (abnormal touch sensations where normal sensations feel unusual or painful) in 20.9% of participants on 12 mg and 8.8% on 9 mg, compared to 0.7% on placebo (BioSpace, Dec 2025)
Stacking BPC 157 With Other Peptides for Tendon Research In the world of advanced peptide research, investigators rarely look at a single compound in a vacuum
Additionally, GlyNAC supplementation resulted in the upregulation of mitophagy and Pax7 expression, as well as downregulation of 8-OHdG, p16INK4, and Muscle POT1 expression, respectively indicating the impacts on loss of proteostasis, stem-cell exhaustion, genomic damage, cellular senescence, and telomere attrition
The peptide has demonstrated effectiveness in healing muscle, tendon, ligament, bone, and even neural tissue, making it valuable for diverse surgical applications